Hostname: page-component-848d4c4894-8kt4b Total loading time: 0 Render date: 2024-06-17T09:16:08.575Z Has data issue: false hasContentIssue false
  • English
  • Français

Risk Factors Related to a Hospital-Associated Cluster of Clostridium difficile PCR Ribotype 027 Infections in Germany During 2007

Published online by Cambridge University Press:  02 January 2015

Bettina Weiss ,
Niels Kleinkauf ,
Tim Eckmanns ,
Matthias an der Heiden ,
Matthias Neumann ,
Harald Michels  and
Andreas Jansen
Bettina Weiss
Affiliation:
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Niels Kleinkauf
Affiliation:
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Tim Eckmanns
Affiliation:
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Matthias an der Heiden
Affiliation:
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
Matthias Neumann
Affiliation:
Hospital “Barmherzige Brüder”, Trier, Germany
Harald Michels
Affiliation:
Local Health Office of Trier-Saarburg, Trier, Germany
Andreas Jansen*
Affiliation:
Department for Infectious Disease Epidemiology, Robert Koch Institute, Berlin, Germany
*
Department for Infectious Disease Epidemiology, Robert Koch Institute, Seestrasse 10, 13353 Berlin, Germany(JansenA@rki.de)
Get access Rights & Permissions [Opens in a new window]

Abstract

In 2007, Clostridium difficile polymerase chain reaction (PCR) ribotype 027 emerged in Germany. We conducted a hospital-based case-control study to identify specific risk factors for infection with this strain. Logistic regression analysis involving 15 case patients and 31 control patients revealed that exposure to fluoroquinolones (matched odds ratio, 36.2; P < .01) or cephalosporins (matched odds ratio, 19.1; P < .01) was independently related to C. difficile PCR ribotype 027 infection.

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 30 , Issue 3 , March 2009 , pp. 282 - 284
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2009

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Spencer, RC. The role of antimicrobial agents in the aetiology of Clostridium difficile-associated disease. J Antimicrob Chemother 1998;41:21–27.CrossRefGoogle ScholarPubMed
2.Bignardi, GE. Risk factors for Clostridium difficile infection. J Hosp Infect 1998;40:1–15.CrossRefGoogle ScholarPubMed
3.Kuijper, EJ, Barbut, F, Brazier, JS, et al.Update of Clostridium difficile infection due to PCR ribotype 027 in Europe, 2008. Euro Surveill 2008;13:pii = 18942.CrossRefGoogle ScholarPubMed
4.McDonald, LC, Killgore, GE, Thompson, A, et al.An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005;353:2433–2441.CrossRefGoogle ScholarPubMed
5.Kleinkauf, N, Weiss, B, Jansen, A, et al.Confirmed cases and report of clusters of severe infections due to Clostridium difficile PCR ribotype 027 in Germany. Euro Surveill 2007;12:pii = 3307.Google ScholarPubMed
6.Kuijper, EJ, Coignard, B, Tuli, P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006;12:2–18.CrossRefGoogle Scholar
7.Charbon, ME, Pompei, P, Ales, KL, MacKinzie, CR. A new method for classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373–383.Google Scholar
8.Pepin, J, Saheb, N, Coulombe, MA, et al.Emergence of fluoroquinolones as the predominant risk factor for Clostridium difficile-associated diarrhea: a cohort study during an epidemic in Quebec. Clin Infect Dis 2005;41:1254–1260.CrossRefGoogle ScholarPubMed
9.Biller, P, Shank, B, Lind, L, et al.Moxifloxacin therapy as a risk factor for Clostridium difficile-associated disease during an outbreak: attempts to control a new epidemic strain. Infect Control Hosp Epidemiol 2007;28:198–201.CrossRefGoogle ScholarPubMed
10.Gerding, DN. Clindamycin, cephalosporins, fluoroquinolones, and Clostridium difficile-associated diarrhea: this is an antimicrobial resistance problem. Clin Infect Dis 2004;38:646–648.CrossRefGoogle ScholarPubMed